| Year |
Citation |
Score |
| 2024 |
Priya B, Chhabria D, Mahesh Dhongdi J, Kirubakaran S. A novel approach to investigate the combinatorial effects of TLK1 (Tousled-Like Kinase1) inhibitors with Temozolomide for glioblastoma therapy. Bioorganic Chemistry. 151: 107643. PMID 39029318 DOI: 10.1016/j.bioorg.2024.107643 |
0.321 |
|
| 2024 |
Dilip H, Thiruvenkatam V, Kirubakaran S. Studies on Methylpyrazole-Substituted Benzimidazoles to Target Infection through IMPDH Inhibition. Acs Infectious Diseases. PMID 38787329 DOI: 10.1021/acsinfecdis.4c00228 |
0.339 |
|
| 2024 |
Sirakanyan SN, Dilip H, Geronikaki A, Spinelli D, Kirubakaran S, Petrou A, Hakobyan EK, Kartsev VG, Paronikyan EG, Yegoryan HA, Yermalovyan LV, Hovakimyan AA. In silico Design, Synthesis and Biological Evaluation of Novel Thieno[3,2-d]pyrimidine Derivatives for Cancer Therapy - A Preliminary Study on the Inhibitory Potential towards ATR Kinase Domain and PIKK Family. Chemistry & Biodiversity. 21: e202302071. PMID 38230843 DOI: 10.1002/cbdv.202302071 |
0.356 |
|
| 2023 |
Johnson D, Hussain J, Bhoir S, Chandrasekaran V, Sahrawat P, Hans T, Khalil MI, De Benedetti A, Thiruvenkatam V, Kirubakaran S. Synthesis, kinetics and cellular studies of new phenothiazine analogs as potent human-TLK inhibitors. Organic & Biomolecular Chemistry. PMID 36785915 DOI: 10.1039/d2ob02191a |
0.544 |
|
| 2022 |
Frasinyuk M, Chhabria D, Kartsev V, Dilip H, Sirakanyan SN, Kirubakaran S, Petrou A, Geronikaki A, Spinelli D. Benzothiazole and Chromone Derivatives as Potential ATR Kinase Inhibitors and Anticancer Agents. Molecules (Basel, Switzerland). 27. PMID 35889508 DOI: 10.3390/molecules27144637 |
0.375 |
|
| 2021 |
Kirubakaran S, Sureshkumar D, Chandrasekaran S. Tetrathiomolybdate and Tetraselenotungstate as Sulfur/Selenium Transfer Reagents: Applications in the Synthesis of New Thio/Seleno Sugars. Chemical Record (New York, N.Y.). PMID 34145726 DOI: 10.1002/tcr.202100097 |
0.607 |
|
| 2020 |
Bhakuni R, Shaik A, Priya B, Kirubakaran S. Characterization of SPK 98, a Torin2 analog, as ATR and mTOR dual kinase inhibitor. Bioorganic & Medicinal Chemistry Letters. 127517. PMID 32911078 DOI: 10.1016/J.Bmcl.2020.127517 |
0.605 |
|
| 2020 |
Singh V, Bhoir S, Chikhale RV, Hussain J, Dwyer D, Bryce RA, Kirubakaran S, De Benedetti A. Generation of Phenothiazine with Potent Anti-TLK1 Activity for Prostate Cancer Therapy. Iscience. 23: 101474. PMID 32905878 DOI: 10.1016/J.Isci.2020.101474 |
0.416 |
|
| 2020 |
Hussain J, Kirubakaran S, Ravi S. The Endeavours in RAS Inhibition - the Past, Present, and Future. Current Topics in Medicinal Chemistry. PMID 32885752 DOI: 10.2174/1568026620666200903163044 |
0.308 |
|
| 2020 |
Hussain J, Chhabria D, Kirubakaran S. Design, synthesis and biological evaluation of new Myo-inositol derivatives as potential RAS inhibitors. Bioorganic & Medicinal Chemistry Letters. 30: 127290. PMID 32631512 DOI: 10.1016/J.Bmcl.2020.127290 |
0.452 |
|
| 2020 |
Shaik A, Kirubakaran S. Evolution of PIKK family kinase inhibitors: A new age cancer therapeutics. Frontiers in Bioscience (Landmark Edition). 25: 1510-1537. PMID 32114443 |
0.432 |
|
| 2020 |
Shaik A, Kirubakaran S. Evolution of PIKK family kinase inhibitors: A new age cancer therapeutics. Frontiers in Bioscience. 25: 1510-1537. DOI: 10.2741/4866 |
0.512 |
|
| 2020 |
Hussain J, Angira D, Hans T, Dubey P, Kirubakaran S, Thiruvenkatam V. Synthesis and characterization of a new class of phenothiazine molecules with 10H-substituted morpholine & piperidine derivatives: A structural insight Journal of Molecular Structure. 1219: 128546. DOI: 10.1016/J.Molstruc.2020.128546 |
0.308 |
|
| 2019 |
Juvale K, Shaik A, Kirubakaran S. Inhibitors of inosine 5'-monophosphate dehydrogenase as emerging new generation antimicrobial agents. Medchemcomm. 10: 1290-1301. PMID 31534651 DOI: 10.1039/C9Md00179D |
0.479 |
|
| 2019 |
Shah CP, Purushothaman G, Thiruvenkatam V, Kirubakaran S, Juvale K, Kharkar PS. Design, synthesis and biological evaluation of Helicobacter pylori inosine 5'-monophosphate dehydrogenase (HpIMPDH) inhibitors. Further optimization of selectivity towards HpIMPDH over human IMPDH2. Bioorganic Chemistry. 87: 753-764. PMID 30974298 DOI: 10.1016/J.Bioorg.2019.04.001 |
0.491 |
|
| 2019 |
Jangra S, Purushothaman G, Juvale K, Ravi S, Menon A, Thiruvenkatam V, Kirubakaran S. Synthesis and In Vitro Enzymatic Studies of New 3-Aryldiazenyl Indoles as Promising Helicobacter pylori IMPDH Inhibitors. Current Topics in Medicinal Chemistry. 19: 376-382. PMID 30827248 DOI: 10.2174/1568026619666190227212334 |
0.357 |
|
| 2019 |
Shaik A, Agarwal HK, Bhakuni R, Kirubakaran S. Novel pyrazolo [4, 3-c] quinolin-3-one derivatives as PDE5A inhibitors. Current Topics in Medicinal Chemistry. PMID 30747070 DOI: 10.2174/1568026619666190208164402 |
0.471 |
|
| 2019 |
Juvale K, Purushothaman G, Singh V, Shaik A, Ravi S, Thiruvenkatam V, Kirubakaran S. Identification of selective inhibitors of Helicobacter pylori IMPDH as a targeted therapy for the infection. Scientific Reports. 9: 190. PMID 30655593 DOI: 10.1038/S41598-018-37490-X |
0.388 |
|
| 2019 |
Bhoir S, Hussain J, Singh V, Chikhale R, Bryce R, Kirubakaran S, DeBenedetti A. Abstract 1264: Design, synthesis and biological evaluation of new phenothiazine derivatives as potential Tousled-like kinase 1 inhibitors in prostate cancer treatment Cancer Research. 79: 1264-1264. DOI: 10.1158/1538-7445.Sabcs18-1264 |
0.451 |
|
| 2018 |
Bhakuni R, Shaik A, Kirubakaran S. Evaluation of Maltose Binding Protein-Tagged hATR Kinase Domain Catalytic Activity with p53 Ser-15 Phosphorylation. Biochemistry. PMID 30380295 DOI: 10.1021/Acs.Biochem.8B00845 |
0.525 |
|
| 2018 |
Shaik A, Bhakuni R, Kirubakaran S. Design, Synthesis, and Docking Studies of New Torin2 Analogs as Potential ATR/mTOR Kinase Inhibitors. Molecules (Basel, Switzerland). 23. PMID 29695073 DOI: 10.3390/Molecules23050992 |
0.615 |
|
| 2018 |
Bhoir S, Shaik A, Thiruvenkatam V, Kirubakaran S. High yield bacterial expression, purification and characterisation of bioactive Human Tousled-like Kinase 1B involved in cancer. Scientific Reports. 8: 4796. PMID 29555908 DOI: 10.1038/S41598-018-22744-5 |
0.492 |
|
| 2018 |
Singh N, Bhakuni R, Kirubakaran S. Abstract 772: High MDC1 expression in cervical cancer cells can affect the chemo- and radiotherapeutic response as its depletion leads to increased cell death Cancer Research. 78: 772-772. DOI: 10.1158/1538-7445.Am2018-772 |
0.316 |
|
| 2017 |
Kirubakaran S, Thiruvenkatam VT, Shaik A. Development of potent and selective inhibitors for ATR: an adjuvant for DNA damage based chemotherapeutics Cancer Research. 77: 3235-3235. DOI: 10.1158/1538-7445.Am2017-3235 |
0.408 |
|
| 2013 |
Liu Q, Xu C, Kirubakaran S, Zhang X, Hur W, Liu Y, Kwiatkowski NP, Wang J, Westover KD, Gao P, Ercan D, Niepel M, Thoreen CC, Kang SA, Patricelli MP, et al. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. Cancer Research. 73: 2574-86. PMID 23436801 DOI: 10.1158/0008-5472.Can-12-1702 |
0.639 |
|
| 2012 |
Kirubakaran S, Gorla SK, Sharling L, Zhang M, Liu X, Ray SS, Macpherson IS, Striepen B, Hedstrom L, Cuny GD. Structure-activity relationship study of selective benzimidazole-based inhibitors of Cryptosporidium parvum IMPDH. Bioorganic & Medicinal Chemistry Letters. 22: 1985-8. PMID 22310229 DOI: 10.1016/J.Bmcl.2012.01.029 |
0.468 |
|
| 2012 |
Liu Q, Kirubakaran S, Hur W, Niepel M, Westover K, Thoreen CC, Wang J, Ni J, Patricelli MP, Vogel K, Riddle S, Waller DL, Traynor R, Sanda T, Zhao Z, et al. Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics. The Journal of Biological Chemistry. 287: 9742-52. PMID 22223645 DOI: 10.1074/Jbc.M111.304485 |
0.659 |
|
| 2010 |
Macpherson IS, Kirubakaran S, Gorla SK, Riera TV, D'Aquino JA, Zhang M, Cuny GD, Hedstrom L. The structural basis of Cryptosporidium -specific IMP dehydrogenase inhibitor selectivity. Journal of the American Chemical Society. 132: 1230-1. PMID 20052976 DOI: 10.1021/Ja909947A |
0.412 |
|
| Show low-probability matches. |